NEOD001 for amyloid light-chain (AL) amyloidosis

featured image
Interventions: Birtamimab (NEOD001)
Indications: Amyloidosis
Year: 2017

Current treatments for AL amyloidosis target the plasma cells in the bone marrow, stopping the production of amyloid. NEOD001 has the potential to target amyloid protein directly in the bloodstream as well as within the organs. It would make the amyloid protein that is in the bloodstream ineffective, and would also clear amyloid protein deposits in tissues, nerves and organs. This has the potential to be the first treatment for AL amyloidosis that could restore organ function.